GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Issuance of Debt

Genexine (XKRX:095700) Issuance of Debt : ₩22,736 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Genexine Issuance of Debt?

Genexine's Issuance of Debt for the three months ended in Mar. 2024 was ₩1,274 Mil.

Genexine's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 was ₩22,736 Mil.

Genexine Issuance of Debt Historical Data

The historical data trend for Genexine's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Issuance of Debt Chart

Genexine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 36,100.00 23,400.00 36,400.00 26,462.03

Genexine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,000.00 13,205.56 6,534.68 1,721.80 1,274.30

Genexine Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩22,736 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genexine Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Genexine's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Issuance of Debt
Comparable Companies
XKRX:228760 XKRX:216080 XKRX:323990 XKRX:334970 XKRX:005690 XKRX:358570 XKRX:199800 XKRX:115450 XKRX:060590 XKRX:011000 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488
Website
http://www.genexine.com
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines